| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MYGN | Common Stock | Options Exercise | $764K | +28.2K | +12.14% | $27.07 | 261K | Aug 5, 2021 | Direct | F1 |
| transaction | MYGN | Common Stock | Sale | -$1M | -28.2K | -10.82% | $35.57 | 233K | Aug 5, 2021 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MYGN | Non-Qualified Stock Option (right to buy) | Options Exercise | $0 | -28.2K | -26.08% | $0.00 | 80K | Aug 5, 2021 | Common Stock | 28.2K | $27.07 | Direct | F1, F3 |
| Id | Content |
|---|---|
| F1 | The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.57 to $35.60, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The shares subject to this option are fully vested and exercisable. |